The First New Hair Loss Drug in 30 Years?

Overview

The video discusses the lack of new FDA-approved hair loss drugs in decades and highlights a potential new entrant: Veradermics, developing a non-hormonal hair loss medication by dermatologist Dr. Reed Waldman.

Key Points and Arguments

Regulatory concern expanding around finasteride’s safety

• In August 2021, the FDA added warnings to finasteride’s label regarding suicidality and suicidal behavior, which the speaker frames as a significant regulatory shift.
• The video also notes similar or ongoing scrutiny in:
  • UK (MHRA)
  • Europe (EMA)
• It describes label changes addressing mood-related risk and regulatory review of whether finasteride should remain authorized.
• A newer FDA warning is mentioned about compounded topical finasteride, suggesting potential mood-related risks that may not be reversible—implying the safety issue may extend beyond oral formulations.

Why innovation in hair loss drugs has been limited

The guest argues that pharmaceutical investment has slowed due to the commercial performance of existing treatments:

• Finasteride/Propecia and minoxidil/Rogaine are described as not achieving blockbuster financial success (despite clinical usefulness).
• The development landscape since the late 1990s included high-profile failures, including:
  • attempts related to pathway targeting
  • device + topical combination strategies
• The video suggests these outcomes left hair loss as an area where companies hesitated to take on development risk.

A changing market environment could enable a new hair loss drug

The discussion contrasts traditional hair loss economics with newer “lifestyle medication” models:

• Hair loss drugs have often been cash-pay / out-of-pocket, unlike some newer categories (notably GLP-1 weight loss drugs), implying cash-pay acceptance may be broader than before.
• The new opportunity is also linked to treatment adherence and tolerability:
  • Rogaine is criticized for high discontinuation because it’s topical.
  • DHT blockers (e.g., finasteride) face patient hesitancy due to concerns about hormonal and mood side effects and have not historically been ideal for broad acceptance—even if risks may be relatively small.

Addressing unmet need—especially for women

• The guest emphasizes there has been no approved oral DHT-blocker specifically for women with female pattern hair loss.
• Women are described as a majority of treatment-seeking patients.
• The video argues a non-hormonal oral therapy could be transformative by expanding eligibility and improving comfort.

Veradermics Drug: Trial Status

• The company is running two Phase 3 trials in males:
  • Enrollment is underway (about two-thirds enrolled in the first trial)
  • Dosing began for the second trial
• A Phase 3 female trial is expected to begin around mid-year
• The program is designed to enroll approximately ~1,500 participants total across studies

Potential Approval Timeline and Market Implications

• It’s described as uncertain whether male approval would occur before female results.
• If approved, the speaker expects men may switch more readily from finasteride if the new drug avoids:
  • libido/erectile dysfunction
  • mood-change concerns
• This could potentially expand the overall addressable market.

Barriers to Treatment—and How the Company Plans to Address Them

• The video claims only ~1 million people are on prescription hair loss treatments in the U.S., despite far larger numbers experiencing hair-related concerns.
• Two main reasons are offered:
  1. Skepticism that treatments will work
  2. Lack of clarity / decision paralysis in an oversaturated social-media and advertising environment
• Veradermics’ go-to-market approach includes digital patient activation:
  • Ads across platforms (including TikTok/Meta/YouTube) are linked to trial enrollment
  • The company reports a large portion of Phase 3 patients come from these ads
  • It cites strong “interest to participate” metrics, even though trials involve higher-burden action than starting OTC/cosmetic products

Addressing Finasteride Side-Effect Debates

• The video acknowledges that conclusive studies proving finasteride directly causes erectile dysfunction are not fully settled.
• However, regulators are described as interpreting associations based on:
  • the package insert
  • real-world reporting
• It also references concerns about fertility implications:
  • clinicians may stop DHT-blockers 3–4 months before planned pregnancy
  • some reports of successful pregnancies are noted

Reflections on Company Formation

• The founder highlights the difficulty of building a biotech company.
• He emphasizes the importance of assembling the right team/culture and staying close to patient decision-making through real clinic visits.
• He remains partially clinically active to keep connected to patient perspectives.

Presenters / Contributors

• Dr. Reed Waldman — Dermatologist; founder of Veradermics
• Video host/interviewer — A hair transplant surgeon; opening speaker who discusses FDA labeling changes, innovation/safety concerns, trial plans, and go-to-market strategy